NEW YORK, Dec. 6 — Nanogen and RationalDiagnostics will collaborate to develop a microarray to diagnose a range of lymphomas, the two companies announced on Thursday.
By the terms of the agreement, Nanogen will provide the Seattle, Wash.-based clinical genomics company access to a NanoChip molecular biology workstation. RationalDiagnostics in turn will conduct research to identify novel genetic disease markers for lymphoma.
Nanogen, based in San Diego, will retain certain rights to commercialize assays that emerge from the research, the company said in a statement.
Nanogen said that it chose to partner with RationalDiagnostics for its expertise in clinical genomic research and reliance on multiple patient specimens.
Privately held RationalDiagnostics specializes in developing genetic diagnostic tools based on newly identified markers for cancers, autoimmune disorders, infectious diseases, and other illnesses. The company plans to design and market a microarray to help researchers diagnose lymphomas and license lymphoma-related genes to pharmaceutical companies for drug discovery.
According to the American Cancer Society, there were more than 87,000 new lymphoid malignancies reported last year, including Hodgkin's and non-Hodgkin's lymphomas, chronic lymphocytic leukemias, acute lymphoblastic leukemia, and multiple myeloma. There are currently no commercially available diagnostic chips for lymphoma.